A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Inclusion Criteria:
Subjects must give a written, signed and dated informed consent
Chronic plaque-type psoriasis present for at least 6 months before randomization
Moderate to severe plaque psoriasis as defined at randomization by:
Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Sainte-Hyacinthe, Quebec J2S 66, Canada
Bundang Gu, Gyeonggi-do 13620, South Korea